vs
CareDx, Inc.（CDNA）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是CareDx, Inc.的8.1倍（$878.4M vs $108.4M）。CareDx, Inc.净利率更高（-3.8% vs -9.8%，领先6.0%）。CareDx, Inc.同比增速更快（25.2% vs 23.1%）。过去两年CareDx, Inc.的营收复合增速更高（22.7% vs 17.4%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
CDNA vs EXAS — 直观对比
营收规模更大
EXAS
是对方的8.1倍
$108.4M
营收增速更快
CDNA
高出2.1%
23.1%
净利率更高
CDNA
高出6.0%
-9.8%
两年增速更快
CDNA
近两年复合增速
17.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $108.4M | $878.4M |
| 净利润 | $-4.1M | $-86.0M |
| 毛利率 | — | 70.1% |
| 营业利润率 | -5.6% | -9.4% |
| 净利率 | -3.8% | -9.8% |
| 营收同比 | 25.2% | 23.1% |
| 净利润同比 | -104.7% | 90.1% |
| 每股收益（稀释后） | $-0.08 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAEXAS
| Q4 25 | $108.4M | $878.4M | ||
| Q3 25 | $100.1M | $850.7M | ||
| Q2 25 | $86.7M | $811.1M | ||
| Q1 25 | $84.7M | $706.8M | ||
| Q4 24 | $86.6M | $713.4M | ||
| Q3 24 | $82.9M | $708.7M | ||
| Q2 24 | $92.3M | $699.3M | ||
| Q1 24 | $72.0M | $637.5M |
净利润CDNAEXAS
| Q4 25 | $-4.1M | $-86.0M | ||
| Q3 25 | $1.7M | $-19.6M | ||
| Q2 25 | $-8.6M | $-1.2M | ||
| Q1 25 | $-10.4M | $-101.2M | ||
| Q4 24 | $87.7M | $-864.6M | ||
| Q3 24 | $-10.6M | $-38.2M | ||
| Q2 24 | $-4.6M | $-15.8M | ||
| Q1 24 | $-19.9M | $-110.2M |
毛利率CDNAEXAS
| Q4 25 | — | 70.1% | ||
| Q3 25 | — | 68.6% | ||
| Q2 25 | — | 69.3% | ||
| Q1 25 | — | 70.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 69.4% | ||
| Q2 24 | — | 69.8% | ||
| Q1 24 | — | 70.0% |
营业利润率CDNAEXAS
| Q4 25 | -5.6% | -9.4% | ||
| Q3 25 | -0.2% | -3.0% | ||
| Q2 25 | -12.8% | -0.3% | ||
| Q1 25 | -15.8% | -13.6% | ||
| Q4 24 | 97.5% | -122.8% | ||
| Q3 24 | -16.6% | -5.6% | ||
| Q2 24 | -7.9% | -3.8% | ||
| Q1 24 | -31.3% | -16.7% |
净利率CDNAEXAS
| Q4 25 | -3.8% | -9.8% | ||
| Q3 25 | 1.7% | -2.3% | ||
| Q2 25 | -9.9% | -0.1% | ||
| Q1 25 | -12.2% | -14.3% | ||
| Q4 24 | 101.3% | -121.2% | ||
| Q3 24 | -12.8% | -5.4% | ||
| Q2 24 | -5.0% | -2.3% | ||
| Q1 24 | -27.6% | -17.3% |
每股收益（稀释后）CDNAEXAS
| Q4 25 | $-0.08 | $-0.45 | ||
| Q3 25 | $0.03 | $-0.10 | ||
| Q2 25 | $-0.16 | $-0.01 | ||
| Q1 25 | $-0.19 | $-0.54 | ||
| Q4 24 | $1.60 | $-4.69 | ||
| Q3 24 | $-0.20 | $-0.21 | ||
| Q2 24 | $-0.09 | $-0.09 | ||
| Q1 24 | $-0.38 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.2M | $964.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $303.1M | $2.4B |
| 总资产 | $413.2M | $5.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNAEXAS
| Q4 25 | $177.2M | $964.7M | ||
| Q3 25 | $194.2M | $1.0B | ||
| Q2 25 | $186.3M | $858.4M | ||
| Q1 25 | $230.9M | $786.2M | ||
| Q4 24 | $260.7M | $1.0B | ||
| Q3 24 | $240.9M | $1.0B | ||
| Q2 24 | $228.9M | $946.8M | ||
| Q1 24 | $215.9M | $652.1M |
总债务CDNAEXAS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益CDNAEXAS
| Q4 25 | $303.1M | $2.4B | ||
| Q3 25 | $311.1M | $2.5B | ||
| Q2 25 | $327.4M | $2.5B | ||
| Q1 25 | $379.3M | $2.4B | ||
| Q4 24 | $378.4M | $2.4B | ||
| Q3 24 | $273.2M | $3.2B | ||
| Q2 24 | $264.7M | $3.2B | ||
| Q1 24 | $256.2M | $3.1B |
总资产CDNAEXAS
| Q4 25 | $413.2M | $5.9B | ||
| Q3 25 | $432.3M | $5.9B | ||
| Q2 25 | $444.3M | $5.8B | ||
| Q1 25 | $489.6M | $5.7B | ||
| Q4 24 | $491.1M | $5.9B | ||
| Q3 24 | $477.0M | $6.7B | ||
| Q2 24 | $466.8M | $6.7B | ||
| Q1 24 | $452.4M | $6.4B |
负债/权益比CDNAEXAS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $151.7M |
| 自由现金流经营现金流 - 资本支出 | — | $120.4M |
| 自由现金流率自由现金流/营收 | — | 13.7% |
| 资本支出强度资本支出/营收 | — | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $356.8M |
8季度趋势，按日历期对齐
经营现金流CDNAEXAS
| Q4 25 | $21.4M | $151.7M | ||
| Q3 25 | $37.4M | $219.9M | ||
| Q2 25 | $9.9M | $89.0M | ||
| Q1 25 | $-26.6M | $30.8M | ||
| Q4 24 | $21.9M | $47.1M | ||
| Q3 24 | $12.5M | $138.7M | ||
| Q2 24 | $18.9M | $107.1M | ||
| Q1 24 | $-15.3M | $-82.3M |
自由现金流CDNAEXAS
| Q4 25 | — | $120.4M | ||
| Q3 25 | — | $190.0M | ||
| Q2 25 | — | $46.7M | ||
| Q1 25 | — | $-365.0K | ||
| Q4 24 | — | $10.7M | ||
| Q3 24 | — | $112.6M | ||
| Q2 24 | — | $71.2M | ||
| Q1 24 | — | $-120.0M |
自由现金流率CDNAEXAS
| Q4 25 | — | 13.7% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 10.2% | ||
| Q1 24 | — | -18.8% |
资本支出强度CDNAEXAS
| Q4 25 | — | 3.6% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 5.9% |
现金转化率CDNAEXAS
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
